Figure 5

Coexpression of CXCL10/CXCR3 in clinical tumours predicts early metastatic recurrence and reduced survival. (A) Pearson’s correlation analysis of CXCL10 and CXCR3 gene expression values derived from The Cancer Genome Atlas (TCGA) data set. Data are plotted on a log-log scale. Each point corresponds to an individual tumour sample (n=328). (B) Frequencies in expression of CXCL10 and/or CXCR3 in primary melanoma tumours (n=57) and melanoma metastases (n=271) in TCGA. Positive gene expression was defined as an expression value above the median value across all samples. (C) Frequencies of CXCL10/CXCR3 coexpression (blue bar) as compared with CXCL10/CXCR3 nonexpressors (green bar) in primary tumours and metastases (left panel) or specifically in metastases (limited to lymph node, in-transit and distant metastases) (right panel) as a function of distant metastatic recurrence (DM). (D) Rapid distant metastatic recurrence (time to distant metastasis recurrence less than group median; n=19; left panel) and rapid death (time to death less than group median; n=76; right panel) as a function of CXCL10/CXCR3 coexpression. Differences in frequencies were determined using χ² tests.